/ Side by side
Semaglutide vs Orforglipron
A neutral, side-by-side look at Semaglutide and Orforglipron: what each one is, its class, half-life, storage, and the public sources behind it. Educational reference only, not medical advice, dosing, or a recommendation to use either compound.
Semaglutide
Ozempic · Wegovy · Rybelsus
Full profile →Orforglipron
FOUNDAYO · LY3502970
Full profile →| Attribute | Semaglutide | Orforglipron |
|---|---|---|
| Category | GLP-1 / Metabolic | GLP-1 / Metabolic |
| Half-life | ~1 week | ~29-49 h, oral |
| Common vial | 2, 3, 5, 10 mg | 0.8, 2.5, 5.5, 9 mg |
| Reference | Verified | Verified |
What is Semaglutide?
A GLP-1 receptor agonist, acylated for albumin binding and DPP-4 resistance, studied for glycemic control in type 2 diabetes and for weight management. Its long half-life supports once-weekly administration.
Sources
- FDA label: Ozempic, subcutaneous (NDA 209637)
- FDA label: Wegovy, subcutaneous (NDA 215256)
- FDA label: Rybelsus, oral (NDA 213051)
What is Orforglipron?
A non-peptide GLP-1 receptor agonist formulated as a daily tablet rather than an injection, studied for glycemic control in type 2 diabetes and for weight management.
Sources
- FDA label: FOUNDAYO (NDA 220934)
- N Engl J Med 2023: daily oral orforglipron in adults with obesity
- N Engl J Med 2025: orforglipron for obesity treatment
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.